Wedbush Downgrades Voyager Therapeutics (VYGR) to Neutral

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by investment analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Monday, March 12th, MarketBeat.com reports. They presently have a $29.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 66.95% from the company’s previous close.

Several other research firms have also recently issued reports on VYGR. BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, February 24th. BTIG Research reiterated a “buy” rating and issued a $32.00 price objective on shares of Voyager Therapeutics in a research report on Sunday, March 11th. Piper Jaffray reiterated a “buy” rating and issued a $40.00 price objective on shares of Voyager Therapeutics in a research report on Monday, March 12th. Morgan Stanley raised their price target on Voyager Therapeutics from $36.00 to $39.00 and gave the company an “overweight” rating in a research report on Wednesday, February 21st. Finally, Canaccord Genuity restated a “buy” rating and issued a $26.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $29.73.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ VYGR opened at $17.37 on Monday. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $31.91. The firm has a market cap of $619.66, a P/E ratio of -6.58 and a beta of 2.97.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Wednesday, March 14th. The company reported ($0.40) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.32. The firm had revenue of $6.35 million during the quarter, compared to the consensus estimate of $5.81 million. Voyager Therapeutics had a negative return on equity of 63.18% and a negative net margin of 697.03%. analysts anticipate that Voyager Therapeutics will post -2.54 EPS for the current year.

In related news, insider Dinah Ph.D. Sah sold 15,623 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $30.00, for a total transaction of $468,690.00. Following the completion of the transaction, the insider now owns 140,872 shares in the company, valued at approximately $4,226,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jane Henderson sold 17,316 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The shares were sold at an average price of $22.11, for a total value of $382,856.76. Following the transaction, the chief financial officer now owns 15,416 shares of the company’s stock, valued at approximately $340,847.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 68,087 shares of company stock valued at $1,588,741. 8.00% of the stock is currently owned by company insiders.

Large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its position in Voyager Therapeutics by 312.8% during the 3rd quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after purchasing an additional 285,806 shares during the period. Aevitas Wealth Management Inc. acquired a new position in Voyager Therapeutics during the 4th quarter valued at approximately $1,400,000. Vanguard Group Inc. boosted its position in Voyager Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after acquiring an additional 13,194 shares during the period. Bank of New York Mellon Corp boosted its position in Voyager Therapeutics by 16.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 61,858 shares of the company’s stock worth $1,274,000 after acquiring an additional 8,633 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in Voyager Therapeutics during the 4th quarter worth $334,000. Institutional investors and hedge funds own 78.22% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Wedbush Downgrades Voyager Therapeutics (VYGR) to Neutral” was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another website, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The original version of this piece can be viewed at https://baseballnewssource.com/2018/04/07/voyager-therapeutics-vygr-cut-to-neutral-at-wedbush/2038394.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Andujar, Stanton and Torres Shine in Yankees Rout
Andujar, Stanton and Torres Shine in Yankees Rout
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry


Leave a Reply

 
© 2006-2018 BBNS.